NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Monte Rosa Therapeutics director-linked funds restructured their holdings without market trades. On July 1, 2026, New Enterprise Associates 17, L.P. made a pro rata distribution of 1,000,000 shares of Monte Rosa Therapeutics common stock to its general and limited partners for no consideration. NEA Partners 17 both received and later distributed 15,000 shares, also for no consideration. Director Ali Behbahani is a manager of the related general partners and disclaims beneficial ownership of shares in which he has no pecuniary interest, so these entries reflect internal reallocations among NEA-affiliated entities rather than open-market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Behbahani Ali
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock | 1,000,000 | $0.00 | -- |
| Other | Common Stock | 15,000 | $0.00 | -- |
| Other | Common Stock | 15,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 6,692,298 shares (Indirect, See Note 2)
Footnotes (1)
- New Enterprise Associates 17, L.P. ("NEA 17") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026. The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026. The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest. NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026.
Key Figures
Pro rata distribution: 1,000,000 shares
Shares received by NEA Partners 17: 15,000 shares
Shares distributed by NEA Partners 17: 15,000 shares
+2 more
5 metrics
Pro rata distribution
1,000,000 shares
Common Stock distributed by NEA 17 on July 1, 2026
Shares received by NEA Partners 17
15,000 shares
Common Stock received in NEA 17 distribution on July 1, 2026
Shares distributed by NEA Partners 17
15,000 shares
Common Stock distributed for no consideration on July 1, 2026
Indirect holdings after distribution
6,692,298 shares
Common Stock indirectly held by NEA 17 after July 1, 2026 transaction
Restructuring share total
1,030,000 shares
Total Common Stock involved in J-code restructuring transactions
Key Terms
pro rata distribution, general partner, limited partners, beneficial ownership, +2 more
6 terms
pro rata distribution financial
"made a pro rata distribution of 1,000,000 shares of Common Stock"
A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.
general partner financial
"to its general partner and limited partners for no consideration"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
limited partners financial
"to its general partner and limited partners for no consideration"
Limited partners are investors who provide most of the capital to an investment partnership but do not run its day-to-day business; they have liability only up to the amount they invested. Think of them as silent backers who hire a manager to make decisions and share in profits or losses; their importance to investors lies in shaping how much money a fund can deploy, the risk and return profile they receive, and the liquidity and fees associated with that investment.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership, within the meaning of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"in which the Reporting Person has no pecuniary interest"
Section 16 regulatory
"within the meaning of Section 16 of the Securities Exchange Act of 1934"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider activity did GLUE report involving NEA funds?
Monte Rosa Therapeutics reported that NEA-affiliated funds restructured their GLUE holdings. NEA 17 distributed 1,000,000 shares pro rata to partners, while NEA Partners 17 both received and distributed 15,000 shares, all for no consideration as internal reallocations.
Are these GLUE insider transactions likely to impact public float?
The transactions move shares among NEA-related entities and their partners without open-market trades. While beneficial holders change, the 1,000,000 and 15,000 share distributions occur for no consideration and mainly reallocate ownership rather than adding or removing shares from public float.